Sitravatinib
- Generic Name
- Sitravatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C33H29F2N5O4S
- CAS Number
- 1123837-84-2
- Unique Ingredient Identifier
- CWG62Q1VTB
- Background
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
- Conditions
- Lung NeoplasmsMetastatic Lung Non-Small Cell CarcinomaSitravatinibCarcinoma, Non-Small-Cell LungPD-L1 Gene MutationAdvanced Treatment-Naïve PD-L1Lung DiseasesStage IV Lung Non-Small Cell Cancer AJCC v7Pembrolizumab
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sarah Goldberg
- Target Recruit Count
- 9
- Registration Number
- NCT04925986
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 377
- Registration Number
- NCT04921358
- Locations
- 🇨🇳
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇦🇺The Northern Hospital, Epping, Victoria, Australia
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
- Conditions
- Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT04904302
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Indiana University Hospital / IU Simon Cancer Center, Indianapolis, Indiana, United States
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Conditions
- Advanced or Metastatic Solid Malignancies
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04887870
- Locations
- 🇺🇸
Local Institution - 516-014-004, Columbus, Ohio, United States
🇺🇸Local Institution - 516-014-011, Albany, New York, United States
🇺🇸Local Institution - 516-014-027, Fairfax, Virginia, United States
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04887194
- Locations
- 🇺🇸
Goshen Health, Goshen, Indiana, United States
🇺🇸MultiCare Health System, Tacoma, Washington, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04800614
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04772612
- Locations
- 🇺🇸
Texas Liver Institute, Austin, Texas, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Nucleus Network, Saint Paul, Minnesota, United States
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 98
- Registration Number
- NCT04734262
- Locations
- 🇨🇳
Fudan University Shanghai Cancer, Shanghai, Shanghai, China
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT04727996
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
- Conditions
- Clear-Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04518046
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.